EMA Recommends Extending Indications for Lisocabtagene Maraleucel By Ogkologos - November 12, 2025 114 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of adult patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less FDA Approves Acalabrutinib with Venetoclax for CLL or SLL No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC MOST POPULAR Zero Mutation ctDNA Triage for Selection of Patients with Metastatic Colorectal... August 17, 2022 How Running and Training for a Marathon Helped Me Cope After... August 22, 2023 Army Veteran Gets Life-Saving Heart Transplant: ‘It’s A True Miracle’ November 29, 2021 Adding Atezolizumab to Chemotherapy Does Not Improve Outcomes in Patients Who... June 4, 2024 Load more HOT NEWS FDA Approves Olaparib with Abiraterone and Prednisone (or Prednisolone) for BRCA-mutated... Sun Exposure Lowers Risk of Breast Cancer, Study Finds Teen Helps Mom With Cancer Shave Her Head, Then Turns To... Doctors Want Breast Cancer Warning Label Put On Cheese
